ORKA
Oruka Therapeutics, Inc.
Price Chart
Latest Quote
$83.47
-3.18 (-3.67%)
Current Price
| Previous Close | $86.65 |
| Open | $84.92 |
| Day High | $86.26 |
| Day Low | $82.57 |
| Volume | 313,150 |
Stock Information
| Shares Outstanding | 60.31M |
| Total Debt | $1.81M |
| Cash Equivalents | $388.83M |
| Net Income | $-94.19M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.59B |
| EPS (TTM) | $-2.15 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.21B |
| Income | $-94.19M |
| Book/sh | $9.64 |
| Cash/sh | $6.45 |
| Employees | 68 |
Financial Ratios
| Quick Ratio | 23.38 |
| Current Ratio | 23.76 |
| Debt/Eq | 0.37 |
Returns & Margins
| ROA | -18.92% |
| ROE | -27.31% |
Ownership
| Insider Ownership | 1.23% |
| Institutional Ownership | 89.70% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -37.20 |
| P/B | 9.61 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $144.67 |
Technical Indicators
| SMA20 | $86.41 |
| SMA50 | $72.12 |
| SMA200 | $45.47 |
| RSI | 52.46 |
| ATR | 5.7529 |
| Shares Float | 51.09M |
| Short Float | 23.15% |
| Short Ratio | 5.59 |
| Rel Volume | 1.48 |
Performance History
| Week | +6.81% |
| Month | +36.91% |
| Quarter | +38.21% |
| 6 Months | +189.69% |
| YTD | +227.91% |
| Year | +526.35% |
| 3 Years | +597.26% |
| 5 Years | +290.31% |
| 10 Years | -74.01% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $92.70 | 2,804,600 |
| 2026-07-16 | $83.04 | 560,700 |
| 2026-07-15 | $86.65 | 825,200 |
| 2026-07-14 | $87.47 | 900,300 |
| 2026-07-13 | $84.56 | 769,800 |
| 2026-07-10 | $86.79 | 503,000 |
| 2026-07-09 | $88.27 | 560,900 |
| 2026-07-08 | $84.40 | 1,042,700 |
| 2026-07-07 | $84.50 | 2,202,800 |
| 2026-07-06 | $83.13 | 1,579,400 |
| 2026-07-02 | $85.21 | 4,524,000 |
| 2026-07-01 | $93.29 | 1,483,600 |
| 2026-06-30 | $95.17 | 1,755,500 |
| 2026-06-29 | $92.49 | 1,735,300 |
| 2026-06-26 | $90.60 | 4,733,600 |
| 2026-06-25 | $86.63 | 1,806,300 |
| 2026-06-24 | $82.09 | 1,640,900 |
| 2026-06-23 | $83.40 | 1,328,200 |
| 2026-06-22 | $85.38 | 4,201,100 |
| 2026-06-18 | $72.34 | 2,986,500 |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
đ° Latest News
HMI Capital Pares Its Stake in AI Company nCino
Barrons.com âĸ 2026-07-10T23:26:00Z
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
Insider Monkey âĸ 2026-07-01T21:23:33Z
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
Motley Fool âĸ 2026-06-27T19:48:05Z
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Motley Fool âĸ 2026-06-24T21:44:01Z
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-06-12T16:00:03Z
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
Zacks âĸ 2026-06-10T13:55:04Z
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
Motley Fool âĸ 2026-05-31T14:41:54Z
Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding
Simply Wall St. âĸ 2026-05-15T15:18:34Z
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
Motley Fool âĸ 2026-05-13T21:06:33Z
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
Motley Fool âĸ 2026-05-13T20:30:31Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Revenue | |
| Total Revenue | $0 |
| Operating Revenue | $0 |
| Expenses | |
| Interest Expense | $0 |
| Total Expenses | $122,051,000 |
| Other Income Expense | $-12,000 |
| Other Non Operating Income Expenses | $-12,000 |
| Net Non Operating Interest Income Expense | $16,630,000 |
| Interest Expense Non Operating | $0 |
| Operating Expense | $122,051,000 |
| General And Administrative Expense | $21,411,000 |
| Income & Earnings | |
| Net Income From Continuing Operation Net Minority Interest | $-105,433,000 |
| Net Interest Income | $16,630,000 |
| Interest Income | $16,630,000 |
| Normalized Income | $-105,433,000 |
| Net Income From Continuing And Discontinued Operation | $-105,433,000 |
| Total Operating Income As Reported | $-122,051,000 |
| Net Income Common Stockholders | $-105,433,000 |
| Net Income | $-105,433,000 |
| Net Income Including Noncontrolling Interests | $-105,433,000 |
| Net Income Continuous Operations | $-105,433,000 |
| Pretax Income | $-105,433,000 |
| Interest Income Non Operating | $16,630,000 |
| Operating Income | $-122,051,000 |
| Per Share | |
| Diluted EPS | $-1.85 |
| Basic EPS | $-1.85 |
| Other | |
| Tax Effect Of Unusual Items | $0 |
| Tax Rate For Calcs | $0 |
| Normalized EBITDA (Bullshit earnings) | $-105,350,000 |
| Reconciled Depreciation | $83,000 |
| EBITDA (Bullshit earnings) | $-105,350,000 |
| EBIT | $-105,433,000 |
| Diluted Average Shares | $45,614,142 |
| Basic Average Shares | $45,614,142 |
| Diluted NI Availto Com Stockholders | $-105,433,000 |
| Research And Development | $100,640,000 |
| Selling General And Administration | $21,411,000 |
| Other Gand A | $6,379,000 |
| Salaries And Wages | $15,032,000 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $468,999,000 | $379,290,000 |
| Total Assets | $488,617,000 | $396,019,000 |
| Total Non Current Assets | $144,760,000 | $19,150,000 |
| Other Non Current Assets | $103,000 | $43,000 |
| Investmentin Financial Assets | $142,539,000 | $18,069,000 |
| Current Assets | $343,857,000 | $376,869,000 |
| Other Current Assets | $6,813,000 | $1,221,000 |
| Cash Cash Equivalents And Short Term Investments | $337,044,000 | $375,648,000 |
| Cash And Cash Equivalents | $46,935,000 | $61,575,000 |
| Receivables | - | $0 |
| Debt | ||
| Total Debt | $1,932,000 | $968,000 |
| Long Term Debt And Capital Lease Obligation | $1,313,000 | $755,000 |
| Current Debt And Capital Lease Obligation | $619,000 | $213,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $19,618,000 | $16,729,000 |
| Total Non Current Liabilities Net Minority Interest | $4,244,000 | $3,686,000 |
| Current Liabilities | $15,374,000 | $13,043,000 |
| Payables And Accrued Expenses | $9,489,000 | $10,789,000 |
| Payables | $4,164,000 | $9,484,000 |
| Accounts Payable | $4,155,000 | $3,462,000 |
| Equity | ||
| Common Stock Equity | $468,999,000 | $379,290,000 |
| Total Equity Gross Minority Interest | $468,999,000 | $379,290,000 |
| Stockholders Equity | $468,999,000 | $379,290,000 |
| Gains Losses Not Affecting Retained Earnings | $546,000 | $-41,000 |
| Other Equity Adjustments | $546,000 | $-41,000 |
| Retained Earnings | $-189,157,000 | $-83,724,000 |
| Preferred Securities Outside Stock Equity | $2,931,000 | $2,931,000 |
| Preferred Stock Equity | - | $2,931,000 |
| Other | ||
| Ordinary Shares Number | $48,722,309 | $37,440,510 |
| Share Issued | $48,722,309 | $37,440,510 |
| Tangible Book Value | $468,999,000 | $379,290,000 |
| Invested Capital | $468,999,000 | $379,290,000 |
| Working Capital | $328,483,000 | $363,826,000 |
| Capital Lease Obligations | $1,932,000 | $968,000 |
| Total Capitalization | $468,999,000 | $379,290,000 |
| Additional Paid In Capital | $657,561,000 | $463,018,000 |
| Capital Stock | $49,000 | $37,000 |
| Common Stock | $49,000 | $37,000 |
| Long Term Capital Lease Obligation | $1,313,000 | $755,000 |
| Current Capital Lease Obligation | $619,000 | $213,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,266,000 | $2,041,000 |
| Current Accrued Expenses | $5,325,000 | $1,305,000 |
| Dueto Related Parties Current | $9,000 | $6,022,000 |
| Investments And Advances | $142,539,000 | $18,069,000 |
| Available For Sale Securities | $142,539,000 | $18,069,000 |
| Net PPE | $2,118,000 | $1,038,000 |
| Gross PPE | $2,118,000 | $1,038,000 |
| Other Properties | $2,118,000 | $1,038,000 |
| Other Short Term Investments | $290,109,000 | $314,073,000 |
| Preferred Stock | - | $2,931,000 |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-88,419,000 |
| Operating Activities | |
| Operating Cash Flow | $-88,210,000 |
| Cash Flow From Continuing Operating Activities | $-88,210,000 |
| Investing Activities | |
| Capital Expenditure | $-209,000 |
| Investing Cash Flow | $-96,745,000 |
| Cash Flow From Continuing Investing Activities | $-96,745,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $671,000 |
| Financing Cash Flow | $170,315,000 |
| Cash Flow From Continuing Financing Activities | $170,315,000 |
| Net Other Financing Charges | $169,644,000 |
| Net Preferred Stock Issuance | $0 |
| Preferred Stock Issuance | $0 |
| Net Common Stock Issuance | $671,000 |
| Common Stock Issuance | $671,000 |
| Other | |
| Issuance Of Debt | $0 |
| End Cash Position | $46,935,000 |
| Beginning Cash Position | $61,575,000 |
| Changes In Cash | $-14,640,000 |
| Net Issuance Payments Of Debt | $0 |
| Net Long Term Debt Issuance | $0 |
| Long Term Debt Issuance | $0 |
| Net Investment Purchase And Sale | $-96,536,000 |
| Sale Of Investment | $424,423,000 |
| Purchase Of Investment | $-520,959,000 |
| Net PPE Purchase And Sale | $-209,000 |
| Purchase Of PPE | $-209,000 |
| Change In Working Capital | $-2,555,000 |
| Change In Other Current Liabilities | $-448,000 |
| Change In Other Current Assets | $-60,000 |
| Change In Payables And Accrued Expense | $1,925,000 |
| Change In Accrued Expense | $7,245,000 |
| Change In Payable | $-5,320,000 |
| Change In Account Payable | $-5,320,000 |
| Change In Prepaid Assets | $-3,972,000 |
| Other Non Cash Items | $-4,545,000 |
| Stock Based Compensation | $24,240,000 |
| Depreciation Amortization Depletion | $83,000 |
| Depreciation And Amortization | $83,000 |
| Depreciation | $83,000 |
| Net Income From Continuing Operations | $-105,433,000 |
Fetched: 2026-07-16